Updated:
908 Devices
Kevin Knopp founded 908 Devices in 2012. Now a public company, it fields over 3,000 handheld and desktop mass-spec units for defense and biopharma.
908 Devices
908 Devices was founded in 2012 by Kevin Knopp and Michael Ramsey, spinning out of the University of North Carolina to commercialize high-pressure mass spectrometry. The firm's underlying technology miniaturizes laboratory-grade analytical instruments into handheld and desktop form factors. Unlike traditional instrument makers that serve a single vertical, 908 Devices deliberately straddles two distinct markets: life sciences research and bioprocessing, and field-based forensics for military and first responders. The company went public via a traditional IPO in December 2020, raising approximately $75 million. The company deploys capital primarily through internal R&D and targeted product-line acquisitions, having purchased Germany's Trace Analytics in 2019 to expand its gas-analysis portfolio. Its product suite splits between the 'Desktop' segment, anchored by the Rebel cell-culture media analyzer for biopharma, and the 'Handheld' segment, featuring the MX908 — a trace-level chemical detector used by the U.S. Department of Defense and the Secret Service to identify fentanyl, explosives, and chemical-warfare agents. Geographically, the firm generates revenue across North America and Europe, with European customers representing roughly a quarter of hardware placements. In 2023, it booked a deal with the U.S. Army for additional MX908 units. As of early 2025, 908 Devices reports roughly $60 million in annual recurring revenue and maintains a headcount of approximately 230 employees, mostly in Boston. The firm deepened its bioprocessing footprint in April 2024 by launching the MAVEN, an on-line bioreactor monitoring device commercialized in partnership with a major CDMO. Unlike typical instruments that require extensive training, the company's products are designed for use by operators who are not mass-spec experts — a go-to-market wedge that replaced a lab technician requirement with an iPhone-style interface. Structurally, 908 Devices does not fit the standard asset-management or family-office profile. The firm is a publicly traded operating company, yet its R&D intensity and acquisition-led growth strategy resemble a venture studio or long-duration holding company for analytical hardware. Knopp retains both the CEO and board chairman roles, keeping final say on capital allocation decisions, while the technology roadmap remains tightly coupled to the academic principles of its UNC origins.
General information
Firm type
Multi Family Office
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
645 Summer Street, Boston, MA 02210, United States
Principals
Kevin J. Knopp
Co-Founder, President & CEO
Sector focus
Frequently asked questions
Is 908 Devices structured as a family office or a traditional asset manager?
It is neither. 908 Devices is a publicly traded operating company (Nasdaq: MASS) that develops and commercializes purpose-built analytical instruments. The firm funds growth through a combination of operating cash flow, R&D reinvestment, and infrequent acquisitions, not by managing outside capital on behalf of families or institutions. Its inclusion in some databases stems from the '908' identifier, which refers to a police radio code for hazardous materials.
What is the firm's primary source of competitive advantage?
The firm integrates high-pressure mass spectrometry into rugged, miniaturized devices that do not require a specialist operator. Its MX908 handheld detector can identify trace-level narcotics, explosives, and chemical agents in the field, matching lab-grade selectivity. This dual-use capability — serving both biopharma process development and military forensics simultaneously — is unusual among instrument makers, which typically optimize for one vertical.
Who runs investment and capital allocation decisions at 908 Devices?
Co-founder Kevin Knopp holds both the President and CEO titles and chairs the board, giving him final authority over organic R&D spending, partnership terms, and any M&A. The company has not disclosed a separate CIO or an investment committee structure. When 908 Devices acquired Trace Analytics in 2019, Knopp was the named decision-maker in deal disclosures.
Does the firm have a meaningful government contracting footprint?
Yes. The handheld product segment is materially dependent on U.S. federal customers, including the Department of Defense, the Department of Homeland Security, the Secret Service, and allied foreign governments. A 2023 contract with the U.S. Army to field additional MX908 units for narcotics and explosives interdiction is a representative win. Public filings consistently list government sales as a major revenue driver.
What sectors or investment stages does 908 Devices avoid?
908 Devices is not a fund and does not deploy capital into external startups. It explicitly avoids the clinical diagnostics market for patient-facing results. The firm's regulatory filings state that its products are for research, forensic, and industrial use only, not for direct medical decision-making. That self-imposed line keeps it out of the FDA's medical-device regulatory pathway.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: